Brands
Dr. Vritika Agrawal launches DermaCute clinic in Mumbai
MUMBAI: India’s booming medical-aesthetics market has a new entrant with attitude. Dr. Vritika Agrawal, dermatologist and clinician, has opened DermaCute clinic in Andheri West, marking her move from consulting room to corner office — and adding momentum to the rise of women-led healthcare entrepreneurship.
Armed with an MBBS and MD in dermatology, Dr. Agrawal steps into business as founder and ceo of DermaCute, a specialist clinic positioned at the intersection of evidence-based medicine, aesthetic science and personalised care. Her pitch is simple but pointed: skin care grounded in science, delivered with empathy, minus the hype.
“DermaCute is not about surface beauty,” says Dr. Agrawal. “It is about trust, precision and treatments that genuinely work — tailored to the individual, not trends.”
The launch lands at a time when India’s medical-aesthetic sector is expanding at speed, projected to grow at more than 16 per cent CAGR over the next decade. Demand is being driven by technology-led treatments, rising disposable incomes and a shift towards specialist-led, boutique clinics — away from one-size-fits-all hospital chains.
DermaCute reflects that shift. The clinic offers skin rejuvenation and anti-ageing programmes, acne and scar management, laser-based pigmentation correction and hair removal, non-invasive body contouring, facial enhancement and personalised medical facials. The emphasis is on measurable outcomes, safety and long-term skin health, delivered in a refined, clinic-first setting.
Dr. Agrawal’s move also underscores a broader change in the industry’s power structure. Women founders are increasingly shaping India’s beauty and wellness economy, bringing clinical credibility, ethical frameworks and patient-first thinking to a sector long dominated by corporate roll-ups and celebrity branding.
By positioning dermaCute as science-backed and results-driven, Dr. Agrawal is betting that today’s patients want more than glow-ups — they want transparency, data and doctors who stay personally accountable.
The ambition does not stop at Andheri. Dr. Agrawal plans to scale DermaCute into a national brand, building a portfolio of specialist clinics focused on dermatology, aesthetics and holistic wellbeing. Growth, she insists, will be measured and medical — not franchised at the expense of standards.
As India’s appetite for advanced skin care accelerates, DermaCute enters the market with a clear message: clinical rigour sells, ethics endure and confidence, when done properly, is good business.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
